Hannah Eastham
Triptolide induces pro-apoptotic effects against medulloblastoma subtypes
Eastham, Hannah; Morovis Marchetti Cassarotti, Julia; Yaqoob, Marriam; Samphire-Noden, Bethan; Greensmith, David; Jones, Matthew
Authors
Julia Morovis Marchetti Cassarotti
Marriam Yaqoob
Bethan Samphire-Noden
Prof David Greensmith D.J.Greensmith@salford.ac.uk
Associate Dean International Development
Dr Matthew Jones M.A.Jones9@salford.ac.uk
Lecturer
Abstract
Introduction
Medulloblastoma is a common cause of cancer in children, accounting for 20-25% of all paediatric brain tumours worldwide (de Medeiros et al., 2019). Whilst current treatments are effective, they are associated with substantial off-target effects, which impact patients’quality of life for decades after remission is achieved (Jones et al., 2023). This necessitates the need for the development of new treatments, with phytochemicals offering a novel source of new compounds. Extracts of Tripterygium wilfordii have been used in Traditional Chinese Medicine for centuries (Shan et al., 2023), with recent evidence suggesting that compounds derived from this species, such as Triptolide, exert anti-cancer effects (Noel et al., 2019). However, there is no evidence of if this effect translates to medulloblastoma. To address this, we sought to elucidate the fundamental anti-medulloblastoma effect of triptolide.
Material and method
The effect of triptolide on medulloblastoma (HD-MB-03,& DAOY) viability was determined using MTT, long-term proliferation and washout assays. Time-lapse live-cell microscopy was utilised to examine the effect of triptolide on cell morphology, cell fate profile and cellular migration. Flow cytometry was used to examine the cell death mechanism (Annexin V/Propidium Iodide) [1].
Result and discussion
Triptolide produced irreversible concentration and time-dependent decreases in medulloblastoma viability in both HD-MB-03 and DAOY cells, with IC50 values afterexposure for 72 hours found to be 18 nM and 169 nM respectively. HD-MB-03 cell fate profiling revealed that exposure to triptolide (10 nM) produced significantconcentration-dependent increases in cellular death within interphase (P < 0.0001) and a significant 38.5 ± 6.9 % increase in the time take to progress through thecell cycle compared to control (P < 0.0001). Morphological analysis showed triptolide to induce blebbing andcellular shrinkage, indicative of apoptosis. Flow cytometric analysis confirmed this, with a significant 5.2-fold increase in apoptotic cells (P = 0.0002) following treatment with triptolide (20 nM) for 72 hours. Triptolide produced no significant impact on cellular migration at all concentrations (5-20 nM) examined.
Conclusion
These data highlight the potential of triptolide as a novel potent treatment for medulloblastoma. Further work is now required to elucidate the molecular mechanism ofaction associated with the observed pro-apoptotic effect.
[1] The study was ethically approved by the University of Salford Ethical Review Board (ID: 3582).
Presentation Conference Type | Conference Abstract |
---|---|
Conference Name | European Association for Cancer Research Congress 2025 |
Start Date | Jun 16, 2025 |
End Date | Jun 19, 2025 |
Acceptance Date | Apr 8, 2025 |
Online Publication Date | Jun 11, 2025 |
Publication Date | Jun 11, 2025 |
Deposit Date | Jun 12, 2025 |
Print ISSN | 1574-7891 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 19 |
Issue | S1 |
Pages | 523-524 |
DOI | https://doi.org/10.1002/1878-0261.70070 |
Ensure healthy lives and promote well-being for all at all ages
You might also like
The role of interleukin-10 in coronary artery disease
(2023)
Thesis
Triptonide induces pro-apoptotic effectsagainst medulloblastoma subtypes
(2025)
Presentation / Conference Contribution
Celastrol induces pro-apoptotic and anti-migratory effects against medulloblastoma subtypes
(2025)
Presentation / Conference Contribution
Do plasma cytokine levels correlate to cardiac function in coronary artery disease?
(2024)
Presentation / Conference Contribution